

Review Form 1.6

Journal Name:	Journal of Advances in Medical and Pharmaceutical Sciences
Manuscript Number:	Ms_JAMPS_78650
Title of the Manuscript:	Soliqua (Lixi Lan): Sustained long term cost efficacy and safety when used in combination with Metformin and Glimepiride
Type of the Article	Research article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljamps.com/index.php/JAMPS/editorial-policy>)

Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments		
Minor REVISION comments	<ol style="list-style-type: none"> 1. Assess long term efficacy and safety of Soliqua in combination with Glimepiride and Metformin in subjects with type 2 diabetes irrespective of BMI in 'real world' experience. CORRECT AS "Assess long term efficacy and safety of Soliqua in combination with Glimepiride and Metformin in subjects with type 2 diabetes irrespective of BMI in 'real world' experience." 2. 30 adults with type 2 diabetes, age range 32-72 years with A1C >7.5% while receiving therapy CORRECT AS "30 adults with type 2 diabetes, age range 32-72 years with HbA1C >7.5% while receiving therapy" 3. Daily dose was increased by 2 units every 3 days until AM blood sugar 80-130 mg/dl was attained or the dose of 60 units was reached. CORRECT AS "Daily dose was increased by 2 units every 3 days until AM fasting plasma glucose of 80-130 mg/dl was attained or the dose of 60 units was reached." 4. Comparisons are conducted between body weights (kg), fasting plasma glucose (FPG) and A1C prior to initiation of combination therapy (pre Rx) and every 3-6 months until the time of analysis (post Rx). CORRECT AS "Comparisons are conducted between body weights (kg), fasting plasma glucose (FPG) and HbA1C prior to initiation of combination therapy (pre Rx) and every 3-6 months until the time of analysis (post Rx)." 5. Subjects were divided into 2 groups according to desirable A1C levels according to recommendations by ADA: 1) desirable A1C is < 7.0%, 2) desirable A1C 7-8 %. CORRECT AS "Subjects were divided into 2 groups according to desirable HbA1C levels according to recommendations by ADA: 1) desirable HbA1C is < 7.0%, 2) desirable HbA1C 7-8 %." 6. Both Fasting plasma glucose (mg/dl) and A1C (%) declined from 167 ± 10 and 9.7 ± 0.8 to 114 ± 4 and 7.6± 0.3 at the time of analyses (post Rx) respectively in the whole cohort. CORRECT AS "Both Fasting plasma glucose (mg/dl) and HbA1C (%) declined from 167 ± 10 and 9.7 ± 0.8 to 114 ± 4 and 7.6± 0.3 at the time of analyses (post Rx) respectively in the whole cohort." 7. In 4 (0.13 %) morbidly obese subjects, FPG and A1C levels CORRECT AS" In 4 (0.13 %) morbidly obese subjects, FPG and HbA1C levels " 8. Type 2 diabetes was confirmed by presence of C-peptide. CORRECT AS "Type 2 diabetes was confirmed by presence of C-peptide." 9. The dose was increased by 2 units every 3 days until AM blood sugar >80<130 mg/dl was attained CORRECT AS "The dose was increased by 2 units every 3 days until AM fasting plasma glucose >80<130 mg/dl was attained" 10. Hypoglycemic events are reported CORRECT AS "Hypoglycemic events were reported" 11. Comparisons are conducted between CORRECT AS "Comparisons were conducted between" 12. Thus, subjects were divided into 2 groups according to desirable A1C levels: CORRECT AS" Thus, subjects were divided into 2 groups according to desirable Hb A1C levels: " 13. In 4 (0.13 %) morbidly obese subjects, fasting plasma glucose and A1C levels CORRECT AS" In 4 (0.13 %) morbidly obese subjects, fasting plasma glucose and HbA1C levels" 14. Desirable A1C (7.0 %) levels were attained and maintained till the time of analysis CORRECT AS "Desirable HbA1C (7.0 %) levels were attained and maintained till 	

Review Form 1.6

	the time of analysis” 15. In group 2, desirable A1C (7- 8 %)CORRECT AS” In group 2, desirable HbA1C (7- 8 %)” 16. In table 1 , 2 and 3 write HbA1C. 17. In table 2 write findings of post Rx 1 above post Rx 2	
Optional/General comments	Overall it is a good article novel and useful please do minor corrections.	

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Nitika Hans
Department, University & Country	Government Medical College, Amritsar, India